{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Calanca N"],"funding":["Conselho Nacional de Desenvolvimento Científico e Tecnológico","Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil","Fundação de Amparo à Pesquisa do Estado de São Paulo","NCI NIH HHS"],"pagination":["741-750"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6615536"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(8)"],"pubmed_abstract":["Alternative protein-coding transcripts of the <i>RASSF1</i> gene have been associated with dual functions in human cancer: while <i>RASSF1C</i> isoform has oncogenic properties, <i>RASSF1A</i> is a tumour suppressor frequently silenced by hypermethylation. Recently, the antisense long non-coding RNA RASSF1 (<i>ANRASSF1)</i> was implicated in a <i>locus</i>-specific mechanism for the <i>RASSF1A</i> epigenetic repression mediated by PRC2 (Polycomb Repressive Complex 2). Here, we evaluated the methylation patterns of the promoter regions of <i>RASSF1A</i> and <i>RASSF1C</i> and the expression levels of these <i>RASSF1</i> transcripts in breast cancer and breast cancer cell lines. As expected, <i>RASSF1C</i> remained unmethylated and <i>RASSF1A</i> was hypermethylated at high frequencies in 75"],"journal":["Epigenetics"],"pubmed_title":["The long non-coding RNA <i>ANRASSF1</i> in the regulation of alternative protein-coding transcripts <i>RASSF1A</i> and <i>RASSF1C</i> in human breast cancer cells: implications to epigenetic therapy."],"pmcid":["PMC6615536"],"funding_grant_id":["Finance Code 001","CNPq Profix","FAPESP grant# 07/59110-9","P30 CA051008"],"pubmed_authors":["Oliveira RA","Paschoal AP","Galindo LT","Munhoz EP","Caldeira JRF","Rogatto SR","Calanca N","Barbosa BM","Cavalli LR","Rainho CA"],"additional_accession":[]},"is_claimable":false,"name":"The long non-coding RNA <i>ANRASSF1</i> in the regulation of alternative protein-coding transcripts <i>RASSF1A</i> and <i>RASSF1C</i> in human breast cancer cells: implications to epigenetic therapy.","description":"Alternative protein-coding transcripts of the <i>RASSF1</i> gene have been associated with dual functions in human cancer: while <i>RASSF1C</i> isoform has oncogenic properties, <i>RASSF1A</i> is a tumour suppressor frequently silenced by hypermethylation. Recently, the antisense long non-coding RNA RASSF1 (<i>ANRASSF1)</i> was implicated in a <i>locus</i>-specific mechanism for the <i>RASSF1A</i> epigenetic repression mediated by PRC2 (Polycomb Repressive Complex 2). Here, we evaluated the methylation patterns of the promoter regions of <i>RASSF1A</i> and <i>RASSF1C</i> and the expression levels of these <i>RASSF1</i> transcripts in breast cancer and breast cancer cell lines. As expected, <i>RASSF1C</i> remained unmethylated and <i>RASSF1A</i> was hypermethylated at high frequencies in 75","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Aug","modification":"2025-04-18T22:11:27.924Z","creation":"2020-05-30T07:02:25Z"},"accession":"S-EPMC6615536","cross_references":{"pubmed":["31062660"],"doi":["10.1080/15592294.2019.1615355"]}}